Treatment group

Disease stages

Mean

(Pg/ml)

Std. Dev

N

Mean diff ± S.E

p-value

Pretreatment

ESBC

102.24

34.09

28

9.96 ± 7.29

0.175

ASBC

92.29

24.03

40

ESBC

102.24

34.09

28

16.76 ± 9.27

0.074

AHMC

85.49

22.32

21

ESBC

102.24

34.09

28

5.06 ± 8.32

0.545

BBT

97.19

36.12

21

ASBC

92.29

24.03

40

6.80 ± 8.75

0.439

AHMC

85.49

22.32

21

ASBC

92.29

24.03

40

4.90 ± 7.74

0.528

BBT

97.19

36.12

21

BBT

97.19

36.12

21

11.70 ± 9.63

0.227

AHMC

85.49

22.32

21

3 months post-treatment

ESBC

95.64

38.89

28

96.24 ± 56.14

0.090

ASBC

191.88

366.68

38

ESBC

95.64

38.89

28

10.15 ± 71.40

0.887

AHMC

85.49

22.32

21

ESBC

95.64

38.89

28

17.19 ± 64.91

0.792

BBT

78.45

11.13

20

ASBC

191.88

366.68

38

106.39 ± 67.39

0.118

AHMC

85.49

22.32

21

ASBC

191.88

366.68

38

113.43 ± 60.47

0.064

BBT

78.45

11.13

20

BBT

78.45

11.13

20

7.04 ± 74.86

0.925

AHMC

85.49

22.32

21

6 months post-treatment

ESBC

93.78

22.12

26

17.03 ± 10.14

0.097

ASBC

102.70

46.72

31

ESBC

93.78

22.12

26

8.30 ± 12.52

0.051

AHMC

85.49

22.32

21

ESBC

93.78

22.12

26

BBT

-

-

-

ASBC

102.70

46.72

31

25.33 ± 11.83

0.036

AHMC

85.49

22.32

21

ASBC

102.70

46.72

31

BBT

-

-

-

BBT

-

-

-

AHMC

85.49

22.32

21